SIA
ASND icon

SkyView Investment Advisors’s Ascendis Pharma A/S ASND Stock Holding History

SkyView Investment Advisors’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-228
Closed -$21K – 177
2023
Q3 		$21K Hold
228
– – 0.01% 319
2023
Q2 		$66K Buy
+228
New +$19.8K 0.02% 393

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

SkyView Investment Advisors's ASND Position: Q4 2023 in Review

SkyView Investment Advisors sold out of Ascendis Pharma A/S (ASND) in Q4 2023, closing a stake of 228 shares — an estimated $21K sold.

SkyView Investment Advisors first reported a position in ASND in Q2 2023 and held it in 2 quarters. The position peaked at $66K in Q2 2023. 185 funds tracked by Wall St. Rank hold ASND as of Q4 2023.

  • SkyView Investment Advisors reported no remaining Ascendis Pharma A/S position as of Q4 2023 after selling out during the quarter.
  • SkyView Investment Advisors sold 228 Ascendis Pharma A/S shares in Q4 2023, an estimated $21K.
  • SkyView Investment Advisors first reported a position in Ascendis Pharma A/S in Q2 2023 and held it in 2 quarters.
  • SkyView Investment Advisors's Ascendis Pharma A/S position peaked at $66K in Q2 2023.
  • 185 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2023.

Based on SkyView Investment Advisors's 13F filing for Q4 2023, filed 15 Feb 2024.